Month: September 2026

Prepayments (CK93) – Nykredit Realkredit A/S

Posted on by Ravi Shankar

To the Nasdaq Copenhagen

Prepayments (CK93)

Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 25 September 2026 in the attached file.

Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.

For further information about data format and contents, please refer to the Nasdaq website.

Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.

Yours sincerely
Nykredit Realkredit A/S

Attachments

Posted in UncategorizedTagged

FRANÇOIS DESNÉ NOMMÉ DIRECTEUR GÉNÉRAL ADJOINT DES POLYMÈRES HAUTE PERFORMANCE ET GAZ FLUORÉS D’ARKEMA ET MEMBRE DU COMITÉ EXÉCUTIF

Posted on by sHq_LoGiNz

PARIS LA DÉFENSE–(BUSINESS WIRE)–Regulatory News: François Desné rejoint Arkema (Paris:AKE) comme Directeur général adjoint des Polymères Haute Performance et Gaz Fluorés et membre du Comité Exécutif du Groupe au 12 octobre 2026. Il succède à Laurent Tellier, nommé Chief Operating Officer (COO) d’Arkema en juillet dernier. Fort de près de 30 ans d’expérience internationale dans l’industrie, François Desné dispose d’une expertise reconnue dans la transformation d’activités industrielles mondia

Posted in UncategorizedTagged

François Desné Appointed Arkema’s Senior Vice President High Performance Polymers and Fluorogases and Member of the Executive Committee

Posted on by sHq_LoGiNz

PARIS LA DÉFENSE–(BUSINESS WIRE)–Regulatory News: François Desné joins Arkema (Paris:AKE) as Senior Vice President High Performance Polymers and Fluorogases and a member of the Group’s Executive Committee, effective 12 October 2026. He succeeds Laurent Tellier, who was appointed Arkema’s Chief Operating Officer (COO) last July. With nearly 30 years of international experience in the industry, François Desné has recognized expertise in transforming global industrial businesses, accelerating gr

Posted in UncategorizedTagged

Exor Press Release – Periodic Report on the Buyback Program

Posted on by Ravi Shankar

Amsterdam, 28 September 2026

EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM

Exor N.V. (AMS: EXO) (“Exor” or the “Company”) announces that, under the first tranche of the share buyback program of up to €125 million announced on 23 September 2026 (the “First Tranche”), the Company has completed the following transactions on Euronext Amsterdam, CBOE DXE, Turquoise Europe and Aquis Exchange Europe:

EURONEXT AMSTERDAM

Trading Date Number of ordinary shares purchased Average price per share excluding fees (€) Total consideration excluding fees (€)
23 September 2026 39,516 72.65 2,870,676.93
24 September 2026 41,464 71.76 2,975,371.14
25 September 2026 41,363 70.85 2,930,700.37
TOTAL 122,343   8,776,748.44

CBOE DXE

Trading Date Number of ordinary shares purchased Average price per share excluding fees (€) Total consideration excluding fees (€)
23 September 2026 27,151 72.64 1,972,159.57
24 September 2026 28,573 71.74 2,049,689.21
25 September 2026 27,636 70.87 1,958,453.47
TOTAL 83,360   5,980,302.25

TURQUOISE EUROPE

Trading Date Number of ordinary shares purchased Average price per share excluding fees (€) Total consideration excluding fees (€)
23 September 2026 4,010 72.63 291,233.08
24 September 2026 4,082 71.85 293,280.90
25 September 2026 4,037 70.89 286,173.28
TOTAL 12,129   870,687.25

AQUIS EXCHANGE EUROPE

Trading Date Number of ordinary shares purchased Average price per share excluding fees (€) Total consideration excluding fees (€)
23 September 2026 5,710 72.67 414,941.82
24 September 2026 5,037 71.75 361,426.30
25 September 2026 4,604 70.85 326,188.93
TOTAL 15,351   1,102,557.05

After these purchases, the total invested amount under the first tranche is approximately €17 million for a total amount of 233,183 ordinary shares purchased.

As of 28 September 2026, the Company held in total 5,271,559 ordinary shares in treasury (2.54% of total ordinary issued share capital)1.

A comprehensive overview of the transactions carried out under the share buyback program, as well as the details of the above transactions, are available on Exor’s corporate website under the Share Buyback section.

1 This corresponds to 0.78% of the total issued share capital including both ordinary shares and special voting shares.

Attachment

Posted in UncategorizedTagged

Unlocking the Growth – Invitation to BioPorto’s investor meeting on October 7 

Posted on by Ravi Shankar

September 28, 2026
News release

Unlocking the Growth – Invitation to BioPorto’s investor meeting on October 7 

As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, we invite you to join us for an afternoon focused on the key drivers that may shape the Company’s future.

At the event, management will provide an update on BioPorto’s commercial progress, regulatory initiatives, strategic priorities, and path toward sustainable growth and cash flow positivity. Participants will also hear independent perspectives from leading clinical experts and capital market specialists on the opportunities created by biomarker-guided diagnostics and the updated KDIGO guidelines.

Key topics include:
✅ Commercial momentum and strategic priorities
✅ Adult Clinical Validation Study update
✅ What the new KDIGO guidelines could mean for biomarker adoption
✅ External perspectives on BioPorto’s investment case and future value drivers
✅ Live Q&A with management and guest speakers

Wednesday, October 7, 2026
3:00 PM – 5:30 PM CET (Registration from 2:30 PM)
 BioPorto A/S, Tuborg Havnevej 15, 2900 Hellerup, Denmark

Register today to secure your participation and gain first-hand insights into BioPorto’s strategy, clinical progress, and future growth opportunities.
Register in the link in the invitation attached or via this link: https://lnkd.in/ej4e8P65

We look forward to welcoming you to BioPorto.

For further information, please contact:

BioPorto A/S
Klaus Juhl Wulff, BioPorto A/S, investor@bioporto.com, C: +45 25 63 39 90

About BioPorto
BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

Posted in UncategorizedTagged

Samenvatting: SPORVIGILANCE richt zich op veiligere geneesmiddelen en besparing van miljarden euro's voor wereldwijde farmaceuticabedrijven die EU IDMP-boetes worden opgelegd

Posted on by sHq_LoGiNz

LONDEN–(BUSINESS WIRE)–Het Britse regtech-bedrijf SPORVIGILANCE richt zich op een van de grootste nalevingsuitdagingen van de farmaceutische sector met een platform dat een snellere route biedt naar IDMP- en SPOR-paraatheid, naleving en beheer. Nu de EMA (European Medicines Agency) gestructureerde gegevens over geneesmiddelen vooropstelt, komen bedrijven onder druk om regulatorische gegevens nauwkeurig, gestandaardiseerd en conform met EMA-vereisten te houden. SPORVIGILANCE vervangt gefragmen

Posted in UncategorizedTagged

SPORVIGILANCE strebt sicherere Arzneimittel und Einsparungen in Milliardenhöhe für die globale Pharmaindustrie an, die mit IDMP-Bußgeldern der EU konfrontiert ist

Posted on by sHq_LoGiNz

LONDON–(BUSINESS WIRE)–Das britische RegTech-Unternehmen SPORVIGILANCE nimmt eine der größten Compliance-Herausforderungen der globalen Pharmaindustrie ins Visier – mit einer Plattform, die einen schnelleren Weg zur IDMP- und SPOR-Bereitschaft, Compliance und Governance bietet. Da die Europäische Arzneimittelagentur (EMA) strukturierte Arzneimitteldaten vorantreibt, stehen Unternehmen unter dem Druck, regulatorische Daten korrekt, standardisiert und im Einklang mit den EMA-Anforderungen zu ha

Posted in UncategorizedTagged

SPORVIGILANCE vise à rendre les médicaments plus sûrs et à faire des économies se chiffrant en milliards d'euros pour l'industrie pharmaceutique mondiale, confrontée aux amendes de l'UE liées à la norme IDMP

Posted on by sHq_LoGiNz

LONDRES–(BUSINESS WIRE)–L’entreprise britannique de technologie réglementaire SPORVIGILANCE s’attaque à l’un des principaux défis de conformité de l’industrie pharmaceutique mondiale grâce à une plateforme permettant d’accélérer la préparation, la conformité et la gouvernance de la norme IDMP et des données SPOR. Alors que l’Agence européenne des médicaments fait progresser la structuration des données sur les médicaments, les entreprises sont confrontées à la nécessité de maintenir l’exactit

Posted in UncategorizedTagged

SPORVIGILANCE Targets Safer Medicines and Billion-Euro Savings for Global Pharma Facing EU IDMP Fines

Posted on by sHq_LoGiNz

LONDON–(BUSINESS WIRE)–British regulatory technology company SPORVIGILANCE is targeting one of global pharma’s major compliance challenges with a platform offering a faster route to IDMP and SPOR readiness, compliance and governance. As the European Medicines Agency advances structured medicinal product data, companies face pressure to keep regulatory data accurate, standardised and aligned with EMA requirements. SPORVIGILANCE replaces fragmented manual assessment with a regulatory intelligen

Posted in UncategorizedTagged

Riassunto: SPORVIGILANCE punta a farmaci più sicuri e a risparmi pari a un miliardo di euro per l'industria farmaceutica a livello globale soggetta alle penalità dell'UE in materia di IDMP

Posted on by sHq_LoGiNz

LONDRA–(BUSINESS WIRE)–La società britannica specializzata in tecnologia normativa SPORVIGILANCE punta a una delle maggiori sfide di conformità per il settore farmaceutico globale con una piattaforma che offre un percorso più rapido a preparazione, conformità e governance relative all’IDMP e allo SPOR. Man mano che l’Agenzia europea per i medicinali (EMA) porta avanti dati strutturati di prodotti medicinali, le aziende sono soggette a pressioni per mantenere i dati accurati, standardizzati e

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance (opens in a new tab)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.